Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Seminars in Immunopathology
Published in: Seminars in Immunopathology 4/2007

01-11-2007 | Review

Infection and glomerulonephritis

Authors: Saraladevi Naicker, June Fabian, Sagren Naidoo, Shoyab Wadee, Graham Paget, Stewart Goetsch

Published in: Seminars in Immunopathology | Issue 4/2007

Login to get access

Abstract

Glomerular injury, occurring either as primary glomerular disease or as part of a systemic disease process, is usually a result of immune-mediated mechanisms. The morphologic reaction pattern has a diverse spectrum of appearance, ranging from normal by light microscopy in minimal change disease to crescentic forms of glomerulonephritis, with conspicuous disruption of the normal glomerular morphology. The mechanisms of glomerular immune deposit formation include trapping of circulating antigen–antibody complexes and the in situ formation of immune complexes within the glomerulus. While the majority of postinfectious immune-complex-mediated glomerulonephritides are believed to result from the deposition of circulating antigen–antibody complexes, preformed outside of the kidney and secondarily deposited in the kidney, the notion of forming in situ antigen–antibody complexes to either planted antigens or to integral structural components of the glomerulus, through “cross-reacting” autoimmune reactions, is gaining popularity in a variety of forms of glomerulonephritides. Patients with HIV infection may develop a spectrum of renal pathology, the glomerular manifestations of which include both antigen–antibody complex and nonimmune-complex-mediated pathogenetic mechanisms. Similarly, patients with Streptococcal infections, Hepatitis B virus, or Hepatitis C virus infection may develop a spectrum of glomerulonephritides, which are predominantly immune-complex-mediated. Therapy for glomerular diseases due to HIV, hepatitis B, or C virus infections remains a challenge.
Literature
1.
Krogstad P (2003) Molecular biology of the human immunodeficiency virus: current and future targets for intervention. Semin Pediatr Infect Dis 14(4):258–268PubMed
2.
Apetrei C, Marx PA, Smith SM (2004) The evolution of HIV and its consequences. Infect Dis Clin N Am 18:369–394
3.
Sreepada Rao TK (2001) Human immunodeficiency virus infection and renal failure. Infect Dis Clin N Am 15(3):833–850
4.
Kimmel P (2000) The nephropathies of HIV infection: pathogenesis and treatment. Curr Opin Nephrol Hypertens 9(2):117–122PubMed
5.
Di Belgiojoso GB, Ferrario F, Landriani N (2002) Virus-related glomerular diseases: histological and clinical aspects. J Nephrol 15:469–479PubMed
6.
Weiner NJ, Goodman JW, Kimmel PL (2003) The HIV-associated renal diseases: current insight into pathogenesis and treatment. Kidney Int 63:1618–1631PubMed
7.
Cohen AH, Nast CC (1988) HIV-associated nephropathy: a unique combined glomerular, tubular and interstitial lesion. Mod Pathol 1:87–97PubMed
8.
Ross MJ et al (2001) Microcyst formation and HIV-1 gene expression occur in multiple nephron segments in HIV-associated nephropathy. J Am Soc Nephrol 12:2645–2651PubMed
9.
Lai AS, Lai KN (2006) Viral nephropathy. Nat Clin Prac Nephrol 2(5):254–262
10.
Kopp JB et al (1992) Progressive glomerulosclerosis and enhanced renal accumulation of basement membrane components in mice transgenic for human immunodeficiency virus type 1 genes. Proc Natl Acad Sci U S A 89:1577–1581PubMed
11.
Bruggeman LA et al (1997) Nephropathy in human immunodeficiency virus-1 transgenic mice is due to renal transgene expression. J Clin Invest 100:84–92
12.
Cohen AH et al (1989) Demonstration of human immunodeficiency virus in renal epithelium in HIV-associated nephropathy. Mod Pathol 2:125–128
13.
Kimmel PL et al (1993) Viral DNA in microdissected renal biopsy tissue from HIV infected patients with nephrotic syndrome. Kidney Int 43:1347–1352
14.
Bruggeman LA et al (2000) Renal epithelium is a previously unrecognised site of HIV-1 infection. J Am Soc Nephrol 11:2079–2087
15.
Dickie P et al (1991) HIV-associated nephropathy in transgenic mice expressing HIV-1 genes. Virology 185:109–119
16.
Tanji N et al (2006) Detection and localization of HIV-1 DNA in renal tissues by in-situ polymerase chain reaction. Histol Histopathol 21:393–401
17.
Eitner F et al (2000) Chemokine receptor CCR5 and CXCR4 expression in HIV-associated kidney disease. Immunol Pathol 11(5):856–867
18.
Eitner F et al (1998) Chemokine receptor (CCR5) expression in human kidneys and in the HIV infected macaque. Kidney Int 54:1945–1954
19.
Conaldi PG et al (1998) HIV-1 kills renal tubular epithelial cells in vitro by triggering an apoptotic pathway involving caspase activation and Fas upregulation. J Clin Invest 102:2041–2049
20.
Huber TB et al (2002) Expression of functional CCR and CXCR chemokine receptors in podocytes. J Immunol 168:6244–6252PubMed
21.
Gerntholtz TE, Goetsch SJ, Katz I (2006) HIV-related nephropathy: a South African perspective. Kidney Int 69:1885–1891PubMed
22.
Singhal PC, Sharma P, Loona R (1998) Enhanced proliferation, apoptosis, and matrix accumultaion by mesangial cells derived from HIV-1 transgenic mice. J Investig Med 46:297–302PubMed
23.
Singhal PC, Sharma P, Reddy K (1997) HIV-1 gp160 envelope protein modulates proliferation and apoptosis in mesangial cells. Nephron 76:284–295PubMed
24.
Conaldi PG, Botelli A, Wade-Evans A (2000) HIV-persistent infection and cytokine induction in mesangial cells: a potent mechanism for HIV-associated glomerulosclerosis. AIDS 14:2045–2047PubMed
25.
Bodi I, Kimmel PL, Abraham AA (1997) Renal TGF-beta in HIV-associated kidney diseases. Kidney Int 51:1568–1577PubMed
26.
Hiramatsu N et al (2007) Angiotensin II type 1 receptor blockade inhibits the development and progression of HIV-associated nephropathy in a mouse model. J Am Soc Nephrol 18:515–527
27.
Border WA, Noble NA (1994) Transforming growth-factor-beta in tissue fibrosis. N Engl J Med 331:1286–1292PubMed
28.
Wei A et al (2003) Long-term renal survival in HIV-associated nephropathy with angiotensin-converting enzyme inhibition. Kidney Int 64:1462–1471
29.
Mongia A et al (2004) Protease inhibitors modulate apoptosis in mesangial cells derived from a mouse model of HIVAN. Kidney Int 65(3):860–870PubMed
30.
Husain M et al (2002) HIV-Nef induces proliferation and anchorage-independent growth in podocytes. J Am Soc Nephrol 13(12):2997–3004
31.
Lu T, Klotman PE (2007) Podocytes in HIV-associated nephropathy. Nephron Clin Pract 106(2):c67–c71PubMed
32.
Schwartz EJ et al (2001) Human immunodeficiency virus-1 induces loss of contact inhibition in podocytes. J Am Soc Nephrol 12(8):1677–1684PubMed
33.
Doublier S et al (2007) HIV-1 Tat reduces nephrin in human podocytes: a potential mechanism for enhanced glomerular permeability in HIV-associated nephropathy. AIDS 21(4):423–432
34.
Barisoni L et al (1999) The dysregulated podocyte phenotype: a novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 10(1):51–61PubMed
35.
Kaufman L et al (2004) Side-kick-1 is upregulated in glomeruli in HIV-associated nephropathy. J Am Soc Nephrol 15(7):1721–1730
36.
Kaufman L et al (2007) The homophilic adhesion molecule sidekick-1 contributes to augmented podocyte aggregation in HIV-associated nephropathy. FASEB J 21(7):1367–1375
37.
Zhong J et al (2005) Expression of HIV-1 genes in podocytes alone can lead to the full spectrum of HIV-1-associated nephropathy. Kidney Int 68(3):1048–1060
38.
D'Agati V et al (1989) Pathology of HIV-associated nephropathy: a detailed morphological and comparative study. Kidney Int 35:1358–1370
39.
Tang P et al (2005) Fibroblast growth factor-2 increases the renal recruitment and attachment of HIV-infected mononuclear cells to renal tubular epithelial cells. Pediatr Nephrol 20:1708–1716
40.
Ross MJ et al (2006) HIV-1 infection initiates an inflammatory cascade in human renal tubular epithelial cells. J Acquir Immune Defic Syndr 42:1–11
41.
Eustace JA et al (2000) Cohort study of the treatment of severe HIV-associated nephropathy with corticosteroids. Kidney Int 58:1253–1260
42.
Kimmel PL, Mishkin GJ, Umana WO (1996) Captopril and renal survival in patients with human immunodeficiency virus nephropathy. Am J Kidney Dis 28:202–208PubMed
43.
Burns GC et al (1997) Effect of angiotensin-converting enzyme inhibition in HIV-associated nephropathy. J Am Soc Nephrol 8(7):1140–1146
44.
Gupta SK et al (2005) Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV medicine association of the infectious diseases society of America. Clin Infect Dis 40:1559–1585
45.
Ingulli E, Tejani A, Fikrig S (1991) Nephrotic syndrome associated with acquired immunodeficiency syndrome in children. J Pediatr 119(5):710–716PubMed
46.
Winston JA et al (2001) Nephropathy and establishment of a renal reservoir of HIV type 1 during Primary Infection. N Engl J Med 344(26):1979–1984
47.
Szczech LA et al (2002) Protease inhibitors are associated with a slowed progression of HIV-related renal diseases. Clin Nephrol 57:336–341
48.
Furtado MR et al (1999) Persistence of HIV-1 Transcription in Peripheral-Blood Mononuclear Cells in Pateints Receiving Potent Antiretroviral Treatment. N Engl J Med 340(21):1614–1622
49.
Ross MJ, Klotman PE (2004) HIV-associated nephropathy. AIDS 18(8):1089–1099PubMed
50.
Mqhayi M et al (2006) Causes for defaulting antiretrovirals in an urban clinic. in 13th Conference on Retroviruses and Opportunistic Infections (CROI 2006). Denver, USA
51.
Cunningham MW (2000) Pathogenesis of group A streptococcal infections. Clin Microbiol Rev 13(3):470–511PubMed
52.
Fox EN (1974) M proteins of group A streptococci. Bacteriol Rev 38(1):57–86PubMed
53.
Lancefield RC (1969) Current problems in studies of streptococci. J Gen Microbiol 55(2):161–163PubMed
54.
Friedman J et al (1984) Immunological studies of post-streptococcal sequelae. Evidence for presence of streptococcal antigens in circulating immune complexes. J Clin Invest 74(3):1027–1034
55.
Kefalides NA et al (1986) Antibodies to basement membrane collagen and to laminin are present in sera from patients with poststreptococcal glomerulonephritis. J Exp Med 163(3):588–602
56.
Lange CF (1969) Chemistry of cross-reactive fragments of streptococcal cell membrane and human glomerular basement membrane. Transplant Proc 1(4):959–963PubMed
57.
Goroncy-Bermes P, Birkholz S (1988) Pathogenesis of glomerulonephritis following streptococcal infection. Immun Infekt 16(3):100–103PubMed
58.
Lange K, Seligson G, Cronin W (1983) Evidence for the in situ origin of poststreptococcal glomerulonephritis: glomerular localization of endostreptosin and the clinical significance of the subsequent antibody response. Clin Nephrol 19(1):3–10PubMed
59.
Lange K et al (1976) A hitherto unknown streptococcal antigen and its probable relation to acute poststreptococcal glomerulonephritis. Clin Nephrol 5(5):207–215
60.
Cronin WJ, Lange K (1990) Immunologic evidence for the in situ deposition of a cytoplasmic streptococcal antigen (endostreptosin) on the glomerular basement membrane in rats. Clin Nephrol 34(4):143–146PubMed
61.
Poon-King R et al (1993) Identification of an extracellular plasmin binding protein from nephritogenic streptococci. J Exp Med 178(2):759–763
62.
Cu GA et al (1998) Immunohistochemical and serological evidence for the role of streptococcal proteinase in acute post-streptococcal glomerulonephritis. Kidney Int 54(3):819–826
63.
Nordstrand A et al (1998) Streptokinase as a mediator of acute post-streptococcal glomerulonephritis in an experimental mouse model. Infect Immun 66(1):315–321
64.
Nordstrand A, Norgren M, Holm SE (1996) An experimental model for acute poststreptococcal glomerulonephritis in mice. Apmis 104(11):805–816PubMedCrossRef
65.
Glurich I et al (1991) Identification of Streptococcus pyogenes proteins that bind to rabbit kidney in vitro and in vivo. Microb Pathog 10(3):209–220
66.
67.
Han SH (2004) Extrahepatic manifestations of chronic hepatitis B. Clin Liver Dis 8(2):403–418PubMed
68.
Combes B et al (1971) Glomerulonephritis with deposition of Australia antigen–antibody complexes in glomerular basement membrane. Lancet 2(7718):234–237
69.
Levy M, Chen N (1991) Worldwide perspective of hepatitis B-associated glomerulonephritis in the 80s. Kidney Int Suppl 35:S24–S33PubMed
70.
Okayasu T et al (1992) Inherited copper toxicity in Long-Evans cinnamon rats exhibiting spontaneous hepatitis: a model of Wilson’s disease. Pediatr Res 31(3):253–257
71.
Takekoshi Y et al (1991) Immunopathogenetic mechanisms of hepatitis B virus-related glomerulopathy. Kidney Int Suppl 35:S34–S39
72.
Ito H et al (1981) Hepatitis B e antigen-mediated membranous glomerulonephritis. Correlation of ultrastructural changes with HBeAg in the serum and glomeruli. Lab Invest 44(3):214–220
73.
Lai KN, Lai FM, Tam JS (1989) Comparison of polyclonal and monoclonal antibodies in determination of glomerular deposits of hepatitis B virus antigens in hepatitis B virus-associated glomerulonephritides. Am J Clin Pathol 92(2):159–165PubMed
74.
Sasaki T, Hattori T, Mayumi M (1979) A large-scale survey on the prevalence of HBeAG and anti-HBe among asymptomatic carriers of HBV. Correlation with sex, age, HBsAG titre and s-GPT value. Vox Sang 37(4):216–221PubMed
75.
Ohba S et al (1997) Differential localization of s and e antigens in hepatitis B virus-associated glomerulonephritis. Clin Nephrol 48(1):44–47
76.
Lai FM et al (1994) Primary glomerulonephritis with detectable glomerular hepatitis B virus antigens. Am J Surg Pathol 18(2):175–186CrossRef
77.
Venkataseshan VS et al (1990) Hepatitis-B-associated glomerulonephritis: pathology, pathogenesis, and clinical course. Medicine (Baltimore) 69(4):200–216
78.
Johnson RJ, Couser WG (1990) Hepatitis B infection and renal disease: clinical, immunopathogenetic and therapeutic considerations. Kidney Int 37(2):663–676PubMed
79.
Couser WG (1991) Mechanisms of glomerular injury: an overview. Semin Nephrol 11(3):254–258PubMed
80.
Couser WG et al (1978) Experimental glomerulonephritis in the isolated perfused rat kidney. J Clin Invest 62(6):1275–1287
81.
Van Damme BJ et al (1978) Experimental glomerulonephritis in the rat induced by antibodies directed against tubular antigens. V. Fixed glomerular antigens in the pathogenesis of heterologous immune complex glomerulonephritis. Lab Invest 38(4):502–510
82.
Nangaku M, Couser WG (2005) Mechanisms of immune-deposit formation and the mediation of immune renal injury. Clin Exp Nephrol 9(3):183–191PubMed
83.
Couser WG (1985) Mechanisms of glomerular injury in immune-complex disease. Kidney Int 28(3):569–583PubMed
84.
Horl WH, Kerjaschki D (2000) Membranous glomerulonephritis (MGN). J Nephrol 13(4):291–316PubMed
85.
Ronco P, Debiec H (2006) New insights into the pathogenesis of membranous glomerulonephritis. Curr Opin Nephrol Hypertens 15(3):258–263PubMedCrossRef
86.
Czaja AJ (1997) Extrahepatic immunologic features of chronic viral hepatitis. Dig Dis 15(3):125–144PubMed
87.
Nangaku M, Shankland SJ, Couser WG (2005) Cellular response to injury in membranous nephropathy. J Am Soc Nephrol 16(5):1195–1204PubMed
88.
Lai KN, Lo ST, Lai FM (1989) Immunohistochemical study of the membrane attack complex of complement and S-protein in idiopathic and secondary membranous nephropathy. Am J Pathol 135(3):469–476PubMed
89.
Akano N et al (1989) Immunoelectron microscopic localization of membrane attack complex and hepatitis B e antigen in membranous nephropathy. Virchows Arch A Pathol Anat Histopathol 414(4):325–330
90.
Topham PS et al (1999) Complement-mediated injury reversibly disrupts glomerular epithelial cell actin microfilaments and focal adhesions. Kidney Int 55(5):1763–1775
91.
Couser WG (1998) Pathogenesis of glomerular damage in glomerulonephritis. Nephrol Dial Transplant 13(Suppl 1):10–15PubMed
92.
Brandt J et al (1996) Role of the complement membrane attack complex (C5b-9) in mediating experimental mesangioproliferative glomerulonephritis. Kidney Int 49(2):335–343
93.
Bhimma R, Coovadia HM, Adhikari M (1998) Hepatitis B virus-associated nephropathy in black South African children. Pediatr Nephrol 12(6):479–484PubMed
94.
Lai KN, Lai FM (1991) Clinical features and the natural course of hepatitis B virus-related glomerulopathy in adults. Kidney Int Suppl 35:S40–S45PubMed
95.
Lai KN et al (1991) Membranous nephropathy related to hepatitis B virus in adults. N Engl J Med 324(21):1457–1463CrossRef
96.
Lai KN et al (1990) The therapeutic dilemma of the usage of corticosteroid in patients with membranous nephropathy and persistent hepatitis B virus surface antigenaemia. Nephron 54(1):12–17CrossRef
97.
Sayarlioglu H et al (2005) Mycophenolate mofetil use in hepatitis B associated-membranous and membranoproliferative glomerulonephritis induces viral replication. Ann Pharmacother 39(3):573
98.
Bhimma R et al (2002) Treatment of hepatitis B virus-associated nephropathy in black children. Pediatr Nephrol 17(6):393–389
99.
Chung DR et al (1997) Treatment of hepatitis B virus associated glomerulonephritis with recombinant human alpha interferon. Am J Nephrol 17(2):112–117
100.
Lin CY (1995) Treatment of hepatitis B virus-associated membranous nephropathy with recombinant alpha-interferon. Kidney Int 47(1):225–230PubMed
101.
Fabrizi F, Dixit V, Martin P (2006) Meta-analysis: anti-viral therapy of hepatitis B virus-associated glomerulonephritis. Aliment Pharmacol Ther 24(5):781–788PubMed
102.
Tang S et al (2005) Lamivudine in hepatitis B-associated membranous nephropathy. Kidney Int 68(4):1750–1758
103.
Fabrizi F et al (2004) Lamivudine for the treatment of hepatitis B virus-related liver disease after renal transplantation: meta-analysis of clinical trials. Transplantation 77(6):859–864
104.
Farrell GC, Teoh NC (2006) Management of chronic hepatitis B virus infection: a new era of disease control. Intern Med J 36(2):100–113PubMed
105.
Trepo C, Guillevin L (2001) Polyarteritis nodosa and extrahepatic manifestations of HBV infection: the case against autoimmune intervention in pathogenesis. J Autoimmun 16(3):269–274PubMed
106.
Wen YK, Chen ML (2006) Remission of hepatitis B virus-associated membranoproliferative glomerulonephritis in a cirrhotic patient after lamivudine therapy. Clin Nephrol 65(3):211–215PubMed
107.
Alter MJ et al (1992) The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 327(27):1899–905CrossRef
108.
Yamabe H et al (1995) Hepatitis C virus infection and membranoproliferative glomerulonephritis in Japan. J Am Soc Nephrol 6(2):220–223
109.
Philipneri M, Bastani B (2001) Kidney disease in patients with chronic hepatitis C. Curr Gastroenterol Rep 3(1):79–83PubMed
110.
Roccatello D et al (2007) Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis. Am J Kidney Dis 49(1):69–82
111.
D’Amico G (1998) Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis. Kidney Int 54(2):650–671PubMed
112.
McGuire BM et al (2006) Brief communication: glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation. Ann Intern Med 144(10):735–741
113.
Arase Y et al (1998) Glomerulonephritis in autopsy cases with hepatitis C virus infection. Intern Med 37(10):836–840
114.
Agnello V (1997) The etiology and pathophysiology of mixed cryoglobulinemia secondary to hepatitis C virus infection. Springer Semin Immunopathol 19(1):111–129PubMed
115.
Fabrizi F et al (2002) Kidney and liver involvement in cryoglobulinemia. Semin Nephrol 22(4):309–318
116.
Sansonno D et al (1997) Hepatitis C virus-related proteins in kidney tissue from hepatitis C virus-infected patients with cryoglobulinemic membranoproliferative glomerulonephritis. Hepatology 25(5):1237–1244
117.
Madala ND et al (2003) The pathogenesis of membranoproliferative glomerulonephritis in KwaZulu-Natal, South Africa is unrelated to hepatitis C virus infection. Clin Nephrol 60(2):69–73
118.
Segerer S, Nelson PJ, Schlondorff D (2000) Chemokines, chemokine receptors, and renal disease: from basic science to pathophysiologic and therapeutic studies. J Am Soc Nephrol 11(1):152–176PubMed
119.
Johnson RJ et al (1987) New mechanism for glomerular injury. Myeloperoxidase-hydrogen peroxide-halide system. J Clin Invest 79(5):1379–1387CrossRef
120.
Nikolic-Paterson DJ, Atkins RC (2001) The role of macrophages in glomerulonephritis. Nephrol Dial Transplant 16(Suppl 5):3–7PubMed
121.
Wornle M et al (2006) Novel role of toll-like receptor 3 in hepatitis C-associated glomerulonephritis. Am J Pathol 168(2):370–385
122.
Peterson MC (2007) Elevated circulating transforming growth factor beta-1 may explain poorer renal survival in type II diabetics with chronic hepatitis C. Med Sci Monit 13(5):RA50–RA54
123.
Ronco P, Debiec H (2005) Molecular pathomechanisms of membranous nephropathy: from Heymann nephritis to alloimmunization. J Am Soc Nephrol 16(5):1205–1213PubMed
124.
Davenport A et al (1994) Do mesangial immune complex deposits affect the renal prognosis in membranous glomerulonephritis. Clin Nephrol 41(5):271–276
125.
Xie Y et al (2005) Predictive factors for sustained response to interferon treatment in patients with chronic hepatitis C: a randomized, open, and multi-center controlled trial. Hepatobiliary Pancreat Dis Int 4(2):213–219
126.
Xu Zea (1998) Single dose safety (tolerability and pharmocokinetic/pharmacodynamics (PK/PD) following administration of ascending subcutanoeous doses of pegylated-interferon (PEG-INF) and interferon alpha-2a) to healthy subjects [abstract]. Hepatology 28:702A
127.
Manns MP et al (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358(9286):958–965
128.
Hadziyannis SJ et al (2004) Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140(5):346–355
129.
Sabry AA et al (2002) Effect of combination therapy (ribavirin and interferon) in HCV-related glomerulopathy. Nephrol Dial Transplant 17(11):1924–1930
130.
Misiani R et al (1994) Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 330(11):751–756
131.
Johnson RJ et al (1994) Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy. Kidney Int 46(6):1700–1704
132.
Calleja JL et al (1999) Sustained response to interferon-alpha or to interferon-alpha plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinaemia. Aliment Pharmacol Ther 13(9):1179–1186
133.
Alric L et al (2004) Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. Am J Kidney Dis 43(4):617–623
134.
Ohta S et al (1999) Exacerbation of glomerulonephritis in subjects with chronic hepatitis C virus infection after interferon therapy. Am J Kidney Dis 33(6):1040–1048
135.
Madore F, Lazarus JM, Brady HR (1996) Therapeutic plasma exchange in renal diseases. J Am Soc Nephrol 7(3):367–386PubMed
136.
Quartuccio L et al (2006) Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. Rheumatology (Oxford) 45(7):842–846
137.
Kamar N, Rostaing L, Alric L (2006) Treatment of hepatitis C-virus-related glomerulonephritis. Kidney Int 69(3):436–439PubMed
138.
Garini G et al (2005) Hepatitis C virus-related cryoglobulinemia and glomerulonephritis: pathogenesis and therapeutic strategies. Ann Ital Med Int 20(2):71–80
139.
140.
Gentile I et al (2005) Hemolytic anemia during pegylated IFN-alpha2b plus ribavirin treatment for chronic hepatitis C: ribavirin is not always the culprit. J Interferon Cytokine Res 25(5):283–285
141.
Afdhal NH et al (2004) Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 126(5):1302–1311
142.
Gish RG (2006) Treating HCV with ribavirin analogues and ribavirin-like molecules. J Antimicrob Chemother 57(1):8–13PubMed
143.
Russo MW et al (2003) Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am J Gastroenterol 98(7):1610–1615
144.
Pereira BJ, Levey AS (1997) Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int 51(4):981–999PubMed
145.
Carbognin SJ et al (2006) Acute renal allograft rejection following pegylated IFN-alpha treatment for chronic HCV in a repeat allograft recipient on hemodialysis: a case report. Am J Transplant 6(7):1746–1751
146.
Ozgur O et al (1995) Recombinant alpha-interferon in renal allograft recipients with chronic hepatitis C. Nephrol Dial Transplant 10(11):2104–2106
147.
Shu KH et al (2004) Ultralow-dose alpha-interferon plus ribavirin for the treatment of active hepatitis C in renal transplant recipients. Transplantation 77(12):1894–1896
148.
Cruzado JM et al (2003) Pretransplant interferon prevents hepatitis C virus-associated glomerulonephritis in renal allografts by HCV-RNA clearance. Am J Transplant 3(3):357–360
Metadata
Title
Infection and glomerulonephritis
Authors
Saraladevi Naicker
June Fabian
Sagren Naidoo
Shoyab Wadee
Graham Paget
Stewart Goetsch
Publication date
01-11-2007
Publisher
Springer-Verlag
Published in
Seminars in Immunopathology / Issue 4/2007
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI
https://doi.org/10.1007/s00281-007-0088-x

Other articles of this Issue 4/2007

Seminars in Immunopathology 4/2007 Go to the issue

Review

Complement in glomerular injury

Review

B cells in glomerulonephritis: focus on lupus nephritis

Review

Target antigens and nephritogenic antibodies in membranous nephropathy: of rats and men

Review

Immunopathogenesis of IgAN

Introduction

Glomerulonephritis

Review

Leukocytes in glomerular injury
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits